## Miguel Casanovas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8296664/publications.pdf

Version: 2024-02-01

759233 888059 33 529 12 17 h-index citations g-index papers 643 33 33 33 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology, 2006, 118, 1026-1032.	2.9	94
2	Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory Tâcells through programmed death ligand 1. Journal of Allergy and Clinical Immunology, 2016, 138, 558-567.e11.	2.9	91
3	MV140, a sublingual polyvalent bacterial preparation to treat recurrent urinary tract infections, licenses human dendritic cells for generating Th1, Th17, and IL-10 responses via Syk and MyD88. Mucosal Immunology, 2017, 10, 924-935.	6.0	46
4	Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 462-472.	5.6	40
5	Comparative Study of Tolerance between Unmodified and High Doses of Chemically Modified Allergen Vaccines of <i>Dermatophagoides pteronyssinus</i> International Archives of Allergy and Immunology, 2005, 137, 211-218.	2.1	36
6	Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections. Cell Reports, 2022, 38, 110184.	6.4	34
7	Sensitization to indigenous pollen and molds and other outdoor and indoor allergens in allergic patients from saudi arabia, United arab emirates, and Sudan. World Allergy Organization Journal, 2012, 5, 59-65.	3.5	30
8	Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 875-884.	5.7	29
9	Determination of Ole e 1 by enzyme immunoassay and scanning densitometry. Validation by skin-prick testing. Journal of Immunological Methods, 1999, 223, 17-26.	1.4	26
10	Comparison of the allergenicity and Ole e 1 content of 6 varieties of Olea europaea pollen collected during 5 consecutive years. Annals of Allergy, Asthma and Immunology, 2007, 98, 464-470.	1.0	24
11	Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Glycoconjugate Journal, 2016, 33, 93-101.	2.7	21
12	Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. Veterinary Immunology and Immunopathology, 2017, 190, 65-72.	1.2	15
13	Sublingual MV140 for Prevention of Recurrent Urinary Tract Infections. , 2022, 1, .		10
14	Firstâ€inâ€human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3096-3107.	5.7	9
15	A pilot study of immunotherapy in dogs with atopic dermatitis using a mannanâ€ <i>Dermatophagoides farinae</i> allergoid targeting dendritic cells. Veterinary Dermatology, 2018, 29, 449.	1.2	8
16	Safety of immunotherapy with glutaraldehyde modified allergen extracts in children and adults. Allergologia Et Immunopathologia, 2017, 45, 198-207.	1.7	7
17	Immunochemical Characterization of Antigenic Fragments of <i>Olea europaea</i> and <i>Phleum pratense</i> International Archives of Allergy and Immunology, 2001, 124, 73-76.	2.1	5
18	Bacterial immunotherapy in children with wheezing attacks: clinical impact and mechanism of action. , 2019, , .		3

#	Article	IF	Citations
19	MP02-15â€∫IMPACT OF MV140 ON PATIENT RELATED BURDEN OF DISEASE ASSOCIATED WITH THE MANAGEME OF RECURRENT URINARY TRACT INFECTIONS (RUTI). Journal of Urology, 2022, 207, .	.NJ.4	1
20	Evolution of quality of life in patients treated with therapeutic vaccine containing depigmented and polymerized allergen extracts of dermatophagoides pteronyssinus and D. farinae in allergic asthmatic patients. World Allergy Organization Journal, 2007, &NA, S152.	3.5	0
21	Improvement in symptom and medication score after successful treatment with a depigmented and glutaraldehyde-polymerised extract of D. pteronyssinus and D. farinae. World Allergy Organization Journal, 2007, &NA, S243.	3.5	0
22	Double-blind placebo-controlled study of treatment with a depigmented and glutaraldehyde-polymerised extract of dermatophagoides pteronyssinus and D. farinae. World Allergy Organization Journal, 2007, &NA, S242.	3.5	0
23	215â€∫Study of the Allergenic Crossreactivity and Allergenic Composition of Dermatophagoides Pteronyssinus and Blomia Tropicalis. World Allergy Organization Journal, 2012, 5, S71.	3.5	0
24	98â€∫Specific IGE and IGG Binding to Allergoids of Phleum pratense. World Allergy Organization Journal, 2012, 5, S32-S33.	3.5	0
25	20â€fCross-Reactivity Between Olive Pollen and 3 Species of Grasses in Madrid, Spain. World Allergy Organization Journal, 2012, 5, S7.	3.5	O
26	8â€f Allergenic Composition of Polymerized Allergen Extracts of Betula verrucosa, Dermatophagoides Pteronyssinus and Phleum Pratense. World Allergy Organization Journal, 2012, 5, S3.	3.5	0
27	Evaluation of an Indigenous Community Possibly Protected Against Sensitivity to Mites in the Andean Region. Journal of Allergy and Clinical Immunology, 2019, 143, AB221.	2.9	O
28	Mannan-Allergoid Conjugate of House-Dust Mites: First Subcutaneous and Sublingual Dose-Finding Study in Humans. Journal of Allergy and Clinical Immunology, 2020, 145, AB87.	2.9	0
29	Combination of Allergic Asthma Symptom and Medication Scores in Allergen Immunotherapy Trials: A Proposal. International Archives of Allergy and Immunology, 2021, 182, 1-3.	2.1	0
30	Preparing and administering sublingual allergen vaccines., 2020,, 401-408.		0
31	RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations. , 2021, , .		O
32	A randomized, double-blind placebo-controlled first in human study with mannan-conjugated birch pollen allergoids administered subcutaneously to allergic patients. Journal of Allergy and Clinical Immunology, 2022, 149, AB318.	2.9	0
33	Induction of Allergen-Neutralizing IgG4 and IgA Blocking Antibodies Following Subcutaneous Immunotherapy with Mannan-Conjugated Birch Pollen Allergoid. Journal of Allergy and Clinical Immunology, 2022, 149, AB72.	2.9	0